Effect of Monitoring of Step Number on Diabetes

Samsung Medical Center200 enrolled

Overview

In this study, investigators measured the number of steps, blood pressure, blood glucose, and weight in daily life through the smartphone personal health record application for patients with type 2 diabetes. The efficacy of text message intervention, which encourages an increase in the number of steps per week for 12 weeks, on an increase in the number of daily steps and changes in glucose levels, weight, and blood pressure will be investigated. Also, the durability of intervention will be checked after 12 weeks of intervention ending.

This clinical study is a single institution, randomized, prospective study and monitors the average daily number of steps per week using a smartphone personal health record application developed by Samsung Medical Center for patients with type 2 diabetes. The study subjects were divided into five groups such as 1) basal activity (\<2500 steps/day), 2) limited activity (2500-4999 steps/day), 3) low activity (5000-7499 steps/day), 4) somewhat active (7500-9999 steps/day), 5) active (10000-12499 steps/day), 6) highly active (≥12500 steps/day)according to the average number of steps per day. During the 12-week period, the intervention group receives the text messages that encourage step-by-step increments every week, and the control group does not receive text messages. The effect of 12-week step monitoring and education on the change in daily step count will be analyzed. Also, the effect of change in daily step count on glucose level, body weight, and blood pressure will be studied.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

200

Conditions

Type 2 Diabetes Mellitus Physical Activity

Interventions

Text messagesOTHER

Text messages which encourage the increment of daily step count

Eligibility

Sex: ALLMin age: 20 YearsMax age: 69 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with Type 2 diabetes aged 20-69 years * Patients with a HbA1c of less than 8.5% measured during screening (may be replaced by a test value within 3 months of screening visit ) * Patients who have not been prescribed diabetic medication for the past 4 weeks or who have taken more than one oral hypoglycemic agent for more than 12 weeks at a certain dose * BMI ≥ 23 kg/m2 * Available for use Samsung Galaxy S4 or later Android smartphone and wireless internet * Patients who voluntarily agreed to participate in this clinical study Exclusion Criteria: * Diabetes other than type 2 diabetes, including type 1 diabetes, gestational diabetes * Patients who are taking insulin or GLP-1 agonist other than oral hypoglycemic agent * Patients with uncontrolled chronic liver disease * Patients with acute kidney injury * Patients with psychological disorder * Patients who are taking weight lowering agent * Patients with alcohol or drug addiction within the last 3 * Patients who are taking systemic steroid * Patients who are breastfeeding or pregnant * Patients who did not voluntarily agree to the study * Patients who are unsuitable for participation in clinical research

Locations (1)

Samsung Medical Center

Seoul, South Korea

Outcomes

Primary Outcomes

change in daily step count after 12 weeks of intervention

Time frame: Week 12

Secondary Outcomes

mean daily step count after 12 weeks of intervention

Time frame: Week 12

the proportion of patients who reach participant-day during the 12 weeks of intervention

the proportion of patients who reach participant-day during the 12 weeks of intervention The participant-day means the day the participant reach thier upper group of daily step count

Time frame: Week 12

mean daily step count at Week 24

Time frame: Week 24

the proportion of patients who reach participant-day during the Week 13-24

Time frame: Week 24

the proportion of patients whose HbA1c levels <6.5% without severe hypoglycemia

the proportion of patients whose HbA1c levels \<6.5% without severe hypoglycemia

Time frame: Week 12

the proportion of patients whose HbA1c levels <6.5% without severe hypoglycemia

the proportion of patients whose HbA1c levels \<6.5% without severe hypoglycemia

Time frame: Week 24

HbA1c levels

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.